EP1321144A4 - Collyre - Google Patents
CollyreInfo
- Publication number
- EP1321144A4 EP1321144A4 EP01965597A EP01965597A EP1321144A4 EP 1321144 A4 EP1321144 A4 EP 1321144A4 EP 01965597 A EP01965597 A EP 01965597A EP 01965597 A EP01965597 A EP 01965597A EP 1321144 A4 EP1321144 A4 EP 1321144A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prostaglandin derivatives
- water
- liable
- ophthalmic solutions
- eye drops
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CY20111100235T CY1113200T1 (el) | 2000-09-13 | 2011-02-28 | Οφθαλμικες σταγονες |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000277554 | 2000-09-13 | ||
JP2000277554 | 2000-09-13 | ||
PCT/JP2001/007928 WO2002022131A1 (fr) | 2000-09-13 | 2001-09-13 | Collyre |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1321144A1 EP1321144A1 (fr) | 2003-06-25 |
EP1321144A4 true EP1321144A4 (fr) | 2009-07-29 |
EP1321144B1 EP1321144B1 (fr) | 2010-12-08 |
Family
ID=18762864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01965597A Expired - Lifetime EP1321144B1 (fr) | 2000-09-13 | 2001-09-13 | Collyre |
Country Status (14)
Country | Link |
---|---|
US (4) | US20040097592A1 (fr) |
EP (1) | EP1321144B1 (fr) |
KR (1) | KR100854056B1 (fr) |
CN (1) | CN1243548C (fr) |
AT (1) | ATE490761T1 (fr) |
AU (1) | AU2001286210A1 (fr) |
CA (1) | CA2422031C (fr) |
CY (2) | CY1113200T1 (fr) |
DE (1) | DE60143615D1 (fr) |
DK (1) | DK1321144T3 (fr) |
ES (1) | ES2357551T3 (fr) |
NO (1) | NO332650B1 (fr) |
PT (1) | PT1321144E (fr) |
WO (1) | WO2002022131A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100854056B1 (ko) * | 2000-09-13 | 2008-08-26 | 산텐 세이야꾸 가부시키가이샤 | 점안액 |
PT1532981E (pt) * | 2002-08-23 | 2007-12-12 | Santen Pharmaceutical Co Ltd | Colírios estáveis contendo latanoprost como ingrediente activo |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
EP1666043B1 (fr) * | 2003-07-31 | 2009-12-02 | Santen Pharmaceutical Co., Ltd. | Produit contenant de la prostaglandine |
ATE442146T1 (de) | 2003-11-07 | 2009-09-15 | Senju Pharma Co | Pharmazeutische zusammensetzung mit prostaglandin |
CN102526064A (zh) * | 2004-12-09 | 2012-07-04 | 参天制药株式会社 | 含有分子内具有氟原子的前列腺素的制品 |
PT1829545E (pt) * | 2004-12-24 | 2012-05-21 | Santen Pharmaceutical Co Ltd | Produtos contendo derivado de prostaglandina f2á |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
EP1864666B1 (fr) | 2005-03-31 | 2012-08-15 | Asahi Glass Company, Limited | Agent protecteur pour la cellule neuronale retinienne contenant un derive de prostaglandine f2 alpha comme ingredient actif |
RU2392938C2 (ru) | 2005-04-13 | 2010-06-27 | Убе Индастриз, Лтд | Защитное средство для нейронных клеток сетчатки, содержащее в качестве активного ингредиента производные индазола |
CN103768070A (zh) * | 2006-03-13 | 2014-05-07 | 株式会社·R-技术上野 | 水性组合物 |
FR2912207B1 (fr) * | 2007-02-01 | 2012-10-26 | Air Liquide | Procede et appareil de production de monoxyde de carbone par distillation cryogenique |
WO2008123396A1 (fr) * | 2007-03-29 | 2008-10-16 | Santen Pharmaceutical Co., Ltd. | Préparation de gouttes ophtalmiques de type suspension comprenant de la fluorométholone |
EP1985298A1 (fr) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Émulsions ophtalmiques eau dans l'huile contenant des prostaglandines |
TWI544927B (zh) * | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
WO2009131164A1 (fr) * | 2008-04-23 | 2009-10-29 | 大塚製薬株式会社 | Préparation de gouttes ophtalmiques et utilisation |
EP2127638A1 (fr) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Procédé et composition pour traiter l'hypertension oculaire et le glaucome |
EP2328574A1 (fr) * | 2008-08-05 | 2011-06-08 | University College Cork-National University of Ireland, Cork | Traitement de la dégénérescence de la rétine |
RU2482851C2 (ru) * | 2009-02-20 | 2013-05-27 | Микро Лабс Лимитед | Хранение стабильного продукта простагландина |
EP2269575A1 (fr) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Procédé pour améliorer le biodisponibilité du latanoprost |
US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
ES2391721T3 (es) * | 2010-03-01 | 2012-11-29 | Laboratorios Salvat, S.A. | Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído |
EP2452669A1 (fr) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Composition ophtalmique |
EP2567689A1 (fr) * | 2011-09-12 | 2013-03-13 | Visiotact Pharma | Compositions ophtalmiques contenant des dérivés de prostaglandine 2F alpha et de l'acide hyaluronique |
KR102068858B1 (ko) * | 2012-06-08 | 2020-01-21 | 라이온 가부시키가이샤 | 점막용 조성물 |
CN104288092A (zh) * | 2013-07-16 | 2015-01-21 | 广东东阳光药业有限公司 | 拉坦前列素滴眼剂 |
CN104622798B (zh) * | 2014-12-05 | 2017-12-22 | 广东东阳光药业有限公司 | 一种含有他氟前列素的滴眼液及其制备方法 |
WO2018033854A1 (fr) | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Composition ophtalmique et procédé de traitement de l'hypertension oculaire et du glaucome |
EP3603642B1 (fr) | 2017-03-27 | 2024-01-10 | Alcon Inc. | Préparation pharmaceutique |
WO2020013717A1 (fr) | 2018-07-09 | 2020-01-16 | Warszawskie Zaklady Farmaceutyczne Polfa Sa | Dispositif de distribution ophtalmique |
EP3853317A4 (fr) * | 2018-09-21 | 2022-06-22 | PS Therapy Ltd. | Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation |
EP3871660A4 (fr) | 2018-10-25 | 2022-08-17 | Nexmos Co., Ltd. | Composition de gouttes oculaires comprenant de l'aptamin c en tant que principe actif |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0603800A1 (fr) * | 1992-12-21 | 1994-06-29 | Alcon Laboratories, Inc. | Mélanges de prostaglandines pour la thérapie du glaucome |
WO2000003736A1 (fr) * | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Produit de prostaglandine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4310543A (en) * | 1980-10-09 | 1982-01-12 | Hoffmann-La Roche Inc. | Prostaglandin compositions |
ES2052735T3 (es) * | 1987-09-18 | 1994-07-16 | R Tech Ueno Ltd | Un metodo para producir un agente hipotensor ocular. |
KR920002329B1 (ko) * | 1987-12-25 | 1992-03-21 | 산뗑 세이야꾸 가부시끼가이샤 | 항-알레르기성 점안제 |
US5565492A (en) * | 1988-07-18 | 1996-10-15 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
US5486540A (en) * | 1993-10-28 | 1996-01-23 | Allergan, Inc. | Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
DE69714274T3 (de) * | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
JP3480549B2 (ja) * | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
AR002194A1 (es) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
US6235781B1 (en) * | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
AU2183900A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
CN101362518A (zh) * | 1999-01-19 | 2009-02-11 | 法玛西雅厄普约翰美国公司 | γ-照射消毒的聚乙烯包装 |
KR100854056B1 (ko) * | 2000-09-13 | 2008-08-26 | 산텐 세이야꾸 가부시키가이샤 | 점안액 |
TW586946B (en) * | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
EP1666043B1 (fr) * | 2003-07-31 | 2009-12-02 | Santen Pharmaceutical Co., Ltd. | Produit contenant de la prostaglandine |
US20050049311A1 (en) * | 2003-09-03 | 2005-03-03 | Pharmacia & Upjohn Company | Medicinal products comprising prostaglandin compositions and methods of packaging such compositions |
-
2001
- 2001-09-13 KR KR1020037003605A patent/KR100854056B1/ko active IP Right Review Request
- 2001-09-13 US US10/380,401 patent/US20040097592A1/en not_active Abandoned
- 2001-09-13 EP EP01965597A patent/EP1321144B1/fr not_active Expired - Lifetime
- 2001-09-13 DK DK01965597.6T patent/DK1321144T3/da active
- 2001-09-13 CN CNB018156177A patent/CN1243548C/zh not_active Ceased
- 2001-09-13 CA CA2422031A patent/CA2422031C/fr not_active Expired - Lifetime
- 2001-09-13 AU AU2001286210A patent/AU2001286210A1/en not_active Abandoned
- 2001-09-13 DE DE60143615T patent/DE60143615D1/de not_active Expired - Lifetime
- 2001-09-13 ES ES01965597T patent/ES2357551T3/es not_active Expired - Lifetime
- 2001-09-13 AT AT01965597T patent/ATE490761T1/de active
- 2001-09-13 PT PT01965597T patent/PT1321144E/pt unknown
- 2001-09-13 WO PCT/JP2001/007928 patent/WO2002022131A1/fr active Application Filing
-
2003
- 2003-03-12 NO NO20031138A patent/NO332650B1/no not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,068 patent/US20070248697A1/en not_active Abandoned
-
2011
- 2011-02-28 CY CY20111100235T patent/CY1113200T1/el unknown
- 2011-07-28 CY CY2011007C patent/CY2011007I2/el unknown
-
2015
- 2015-12-28 US US14/980,685 patent/US20160106757A1/en not_active Abandoned
-
2018
- 2018-08-21 US US16/106,634 patent/US20180353518A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0603800A1 (fr) * | 1992-12-21 | 1994-06-29 | Alcon Laboratories, Inc. | Mélanges de prostaglandines pour la thérapie du glaucome |
WO2000003736A1 (fr) * | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Produit de prostaglandine |
Also Published As
Publication number | Publication date |
---|---|
US20160106757A1 (en) | 2016-04-21 |
ATE490761T1 (de) | 2010-12-15 |
NO20031138L (no) | 2003-05-12 |
AU2001286210A1 (en) | 2002-03-26 |
PT1321144E (pt) | 2011-03-10 |
US20070248697A1 (en) | 2007-10-25 |
EP1321144B1 (fr) | 2010-12-08 |
US20040097592A1 (en) | 2004-05-20 |
CY2011007I1 (el) | 2014-04-09 |
ES2357551T3 (es) | 2011-04-27 |
WO2002022131A1 (fr) | 2002-03-21 |
DK1321144T3 (da) | 2011-03-07 |
KR100854056B1 (ko) | 2008-08-26 |
CA2422031A1 (fr) | 2003-03-12 |
CN1457256A (zh) | 2003-11-19 |
CY2011007I2 (el) | 2015-08-05 |
EP1321144A1 (fr) | 2003-06-25 |
DE60143615D1 (de) | 2011-01-20 |
KR20030029981A (ko) | 2003-04-16 |
CN1243548C (zh) | 2006-03-01 |
CA2422031C (fr) | 2011-11-15 |
NO20031138D0 (no) | 2003-03-12 |
NO332650B1 (no) | 2012-11-26 |
US20180353518A1 (en) | 2018-12-13 |
CY1113200T1 (el) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1321144A4 (fr) | Collyre | |
EP0766970A3 (fr) | Procédé et composition de désinfection pour lentilles de contact | |
WO1997028827A1 (fr) | Composition ophtalmique possedant une viscosite adaptee | |
WO2002026277A3 (fr) | Solutions stabilisees de peroxyde d'hydrogene | |
AU7385094A (en) | Pharmaceutical compositions for hardly soluble active substances | |
CA2124873A1 (fr) | Inhibiteur de corrosion contenant de l'iode pour les operations d'acidification dans les champs de petrole | |
HK1056510A1 (en) | Minoxidil-containing preparations | |
GR3022990T3 (en) | Ophthalmic compositions containing a cyclosporin. | |
ES2045316T3 (es) | Preparado lubricante carente de jabon, soluble en agua clara. | |
JP2005177515A (ja) | 多価陽イオンキレート剤を用いて、アイケア用品における原生動物の増殖を抑制する方法 | |
CO4410315A1 (es) | Composicion oral que comprende cantidad efectiva de ten- sioactivo y sulfoacetato laurilo de sodio | |
WO2003009802A3 (fr) | Preparations ophtalmiques et dermatologiques antimicrobiennes synergiques contenant du chlore et du peroxyde d'hydrogene | |
TW266154B (fr) | ||
MXPA03000571A (es) | Composicion util para el tratamiento de mastitis de edvino. | |
CA1331122C (fr) | Desinfection de lentilles de contact a la chlorhexidine | |
IL111625A0 (en) | Phosphoric esters for use as crystallisation inhibitors | |
EP0497001A3 (en) | Oxidized-type glutathione alkyl ester | |
EP0349153A3 (fr) | Système stabilisant les compositions liquides d'eau oxygénée et compositions stabilisées de cette manière | |
CA2137578A1 (fr) | Methode de stabilisation de preparations pour verres de contact | |
CA2090911A1 (fr) | Formulations pharmaceutiques aqueuses a base de cromoglycate sodique | |
CA2390996A1 (fr) | Solutions de nettoyage aqueuses contenant des niveaux eleves de n-alkyl-2-pyrrolidine | |
GB0123382D0 (en) | Water soluble package and liquid contents thereof | |
JP2927294B2 (ja) | 液体漂白剤組成物 | |
AU2001242398A1 (en) | Contact lens treating method and composition | |
RU98104644A (ru) | Ингибитор коррозии нефтепромыслового оборудования |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030401 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090625 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 27/02 20060101ALI20090619BHEP Ipc: A61K 47/10 20060101ALI20090619BHEP Ipc: A61K 47/18 20060101ALI20090619BHEP Ipc: A61K 47/44 20060101ALI20090619BHEP Ipc: A61K 47/34 20060101ALI20090619BHEP Ipc: A61K 31/5575 20060101ALI20090619BHEP Ipc: A61K 9/08 20060101AFI20090619BHEP |
|
17Q | First examination report despatched |
Effective date: 20091015 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60143615 Country of ref document: DE Date of ref document: 20110120 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER & PEDRAZZINI AG |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20110302 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2357551 Country of ref document: ES Kind code of ref document: T3 Effective date: 20110427 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20110400573 Country of ref document: GR Effective date: 20110412 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: ASAHI GLASS COMPANY, LIMITED Owner name: SANTEN PHARMACEUTICAL CO., LTD. |
|
26N | No opposition filed |
Effective date: 20110909 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60143615 Country of ref document: DE Effective date: 20110909 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60143615 Country of ref document: DE Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: SANTEN PHARMACEUTICAL CO., LTD., JP Free format text: FORMER OWNER: SANTEN PHARMACEUTICAL CO., LTD., JP |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: AGC INC. Effective date: 20180918 Ref country code: ES Ref legal event code: PC2A Effective date: 20180918 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: SANTEN PHARMACEUTICAL CO., LTD.; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF LEGAL ENTITY; FORMER OWNER NAME: SANTEN PHARMACEUTICAL CO., LTD. Effective date: 20180815 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: HC Owner name: AGC INC.; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE Effective date: 20180822 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: HC Owner name: SANTEN PHARMACEUTICAL CO. LTD.; JP Free format text: FORMER OWNER: ASAHI GLASS COMPANY LIMITED Effective date: 20181002 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60143615 Country of ref document: DE Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 60143615 Country of ref document: DE Owner name: AGC INC., JP Free format text: FORMER OWNERS: ASAHI GLASS CO., LTD., TOKIO/TOKYO, JP; SANTEN PHARMACEUTICAL CO., LTD, OSAKA, JP Ref country code: DE Ref legal event code: R081 Ref document number: 60143615 Country of ref document: DE Owner name: SANTEN PHARMACEUTICAL CO., LTD, JP Free format text: FORMER OWNERS: ASAHI GLASS CO., LTD., TOKIO/TOKYO, JP; SANTEN PHARMACEUTICAL CO., LTD, OSAKA, JP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: HC Ref document number: 490761 Country of ref document: AT Kind code of ref document: T Owner name: AGC INC., JP Effective date: 20190312 Ref country code: AT Ref legal event code: HC Ref document number: 490761 Country of ref document: AT Kind code of ref document: T Owner name: SANTEN PHARMACEUTICAL CO., LTD., JP Effective date: 20190312 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20200814 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20200901 Year of fee payment: 20 Ref country code: IE Payment date: 20200909 Year of fee payment: 20 Ref country code: LU Payment date: 20200824 Year of fee payment: 20 Ref country code: CY Payment date: 20200904 Year of fee payment: 20 Ref country code: TR Payment date: 20200909 Year of fee payment: 20 Ref country code: MC Payment date: 20200826 Year of fee payment: 20 Ref country code: GB Payment date: 20200902 Year of fee payment: 20 Ref country code: GR Payment date: 20200813 Year of fee payment: 20 Ref country code: FR Payment date: 20200812 Year of fee payment: 20 Ref country code: DK Payment date: 20200910 Year of fee payment: 20 Ref country code: FI Payment date: 20200909 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20200916 Year of fee payment: 20 Ref country code: BE Payment date: 20200817 Year of fee payment: 20 Ref country code: SE Payment date: 20200910 Year of fee payment: 20 Ref country code: AT Payment date: 20200825 Year of fee payment: 20 Ref country code: IT Payment date: 20200812 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20201015 Year of fee payment: 20 Ref country code: PT Payment date: 20200929 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60143615 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20210912 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20210913 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20210913 Ref country code: GB Ref legal event code: PE20 Expiry date: 20210912 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MK9A |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 490761 Country of ref document: AT Kind code of ref document: T Effective date: 20210913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210921 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210912 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20211227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210913 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20210914 |